Pfizer Inc.

PFE

US7170811035

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 12:54:56 2026-06-11 pm EDT			5-day change	1st Jan Change
26.18 ^USD	+2.25%		+1.95%	+5.18%

11:03am	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
11:03am	Race to launch weight-loss pill heats up as Novo wins UK approval	RE

PFIZER INC : Barclays reiterates its Sell rating

Published on 05/28/2026 at 03:45 am EDT

MarketScreener with dpa-AFX Analyser

PFIZER INC.

+2.25%

In his latest research note, analyst Emily Field confirms his negative recommendation. The broker Barclays is keeping its Sell rating. The target price is unchanged at USD 25.

Latest news about Pfizer Inc.

11:03am	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
11:03am	Race to launch weight-loss pill heats up as Novo wins UK approval	RE
09:53am	Commission's appeal against COVID vaccine contract disclosures should be dismissed, court adviser says	RE
02:02am	Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal	RE
Jun. 10	Pfizer's Risk-Reward More Balanced Ahead of 2 Key Pipeline Catalysts, RBC Capital Markets Says	MT
Jun. 10	Pfizer CEO warns German investment at risk over drug pricing policies	RE
Jun. 10	Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon	RE
Jun. 10	Analyst recommendations: Nike, Pfizer, Hewlett Packard, Intel, The Trade Desk…
Jun. 10	RBC Upgrades Pfizer to Sector Perform from Underperform, PT is $25	MT
Jun. 09	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
Jun. 08	AstraZeneca's Obesity Pill Helps Patients Lose Weight in Midstage Trials	DJ
Jun. 08	Pfizer Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 08:00 AM
Jun. 08	Markets Ask AI for Receipts
Jun. 08	U.S. FDA Approves Pfizer?s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need	CI
Jun. 08	Pfizer Gets FDA Expanded Hympavzi Approval	DJ

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (47.4%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (26.2%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (24.5%); - other (1.9%). The United States accounts for 60.8% of net sales.

Employees

75,000

Sector

Pharmaceuticals

More about the company